Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Culver who wrote (1373)	1/23/2000 12:18:00 PM
From: Sean Janzen	Read Replies (1) of 1501

Dave, Here's another of IZP's competitors as mentioned in SA Advisory a few years back: saadvisory.com SA Advisory's recommendation in 1996(Conservative Accounts should consider a mini portfolio of 1/4 IZYPF, 1/4 ICOS, 1/4 ARRS, 1/4 ARIA). Nearly 30,000,000 shares of ARIA traded in a single day in early January/00 on this news:ARIAD to Present Key Advances in Regulated Gene Therapy and Gene Activation At Keystone Symposium. Ariad (ARIA) moved from US$0.50 to US$9.75 in 3 months: quote.yahoo.com It currently trades at US$6. I wonder if Inflazyme will get a similar jump on news of the MOA (mode of action) for IZP-576. It would be interesting to know if IZP is involved in either of these two sessions at their next conference, New Developments in Respiratory Disease and Inflammation: A new Pathway to Stop Disease in its Tracks Could this be the conference IZP releases a new pathway? Just wondering!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next